TWI886093B - D-絲胺酸之氘化類似物及其用途 - Google Patents

D-絲胺酸之氘化類似物及其用途 Download PDF

Info

Publication number
TWI886093B
TWI886093B TW107141705A TW107141705A TWI886093B TW I886093 B TWI886093 B TW I886093B TW 107141705 A TW107141705 A TW 107141705A TW 107141705 A TW107141705 A TW 107141705A TW I886093 B TWI886093 B TW I886093B
Authority
TW
Taiwan
Prior art keywords
compound
formula
pharmaceutical composition
serine
certain embodiments
Prior art date
Application number
TW107141705A
Other languages
English (en)
Chinese (zh)
Other versions
TW201924668A (zh
Inventor
達瑞歐 德勒
克里斯多夫 Ｌ 布魯梅爾
茱莉 Ｆ 劉
羅傑 Ｄ 童
Original Assignee
美商太陽製藥工業股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商太陽製藥工業股份有限公司 filed Critical 美商太陽製藥工業股份有限公司
Publication of TW201924668A publication Critical patent/TW201924668A/zh
Application granted granted Critical
Publication of TWI886093B publication Critical patent/TWI886093B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW107141705A 2017-11-22 2018-11-22 D-絲胺酸之氘化類似物及其用途 TWI886093B (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201762590109P 2017-11-22 2017-11-22
US62/590,109 2017-11-22
US201862636081P 2018-02-27 2018-02-27
US62/636,081 2018-02-27
US201862636427P 2018-02-28 2018-02-28
US62/636,427 2018-02-28
US201862755157P 2018-11-02 2018-11-02
US62/755,157 2018-11-02

Publications (2)

Publication Number Publication Date
TW201924668A TW201924668A (zh) 2019-07-01
TWI886093B true TWI886093B (zh) 2025-06-11

Family

ID=64755715

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107141705A TWI886093B (zh) 2017-11-22 2018-11-22 D-絲胺酸之氘化類似物及其用途

Country Status (13)

Country Link
US (4) US20200368193A1 (https=)
EP (2) EP3713557B1 (https=)
JP (3) JP7518765B2 (https=)
KR (1) KR102916897B1 (https=)
CN (1) CN111491629A (https=)
AU (2) AU2018371784B2 (https=)
BR (1) BR112020010156A2 (https=)
CA (1) CA3082834A1 (https=)
IL (2) IL274585B2 (https=)
MX (1) MX2020005336A (https=)
PL (1) PL3713557T3 (https=)
TW (1) TWI886093B (https=)
WO (1) WO2019104179A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111491629A (zh) * 2017-11-22 2020-08-04 康塞特医药品公司 D-丝氨酸的氘化类似物及其用途
RU2738873C2 (ru) * 2018-12-29 2020-12-17 Общество С Ограниченной Ответственностью "Сольвекс" (Ооо "Сольвекс") Препарат для магнитно-резонансной томографии, содержащий дейтерированный саркозин, и способ диагностики с использованием этого препарата
WO2020206367A1 (en) * 2019-04-03 2020-10-08 Concert Pharmaceuticals, Inc. Processes for the preparation of deuterated d-serine
WO2020243638A1 (en) * 2019-05-30 2020-12-03 Concert Pharmaceuticals, Inc. Methods of treatment with deuterated analogs of d-serine
EP4076461B1 (en) * 2019-12-19 2026-01-28 Intra-Cellular Therapies, Inc. Lumateperone for use in schizophrenia treatment
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582931A (en) * 1984-12-24 1986-04-15 Merck & Co., Inc. Preparation of 2-Deutero-D-serine

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6361957B1 (en) 1999-08-03 2002-03-26 Glytech, Inc. Assay for D-serine transport antagonist and use for treating psychosis
PT871440E (pt) 1995-12-07 2006-07-31 Daniel C Javitt Tratamento de sintomas negativos e cognitivos de esquizofrenia com antagonistas da captacao de glicina
US5845286A (en) 1996-12-24 1998-12-01 Colizza; Vincent Date value reduction system
DE1073432T1 (de) * 1998-04-14 2002-02-07 The General Hospital Corp., Boston Verwendung von glycinrezeptoragonisten und glycinaufnahmeinhibitoren zur behandlung neuropsychiatrischer beschwerden
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
US6258605B1 (en) 1999-03-26 2001-07-10 Neo Gen Screening, Inc. Clinical method for the genetic screening of newborns using tandem mass spectrometry
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
PT1104760E (pt) 1999-12-03 2003-06-30 Pfizer Prod Inc Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
HU229938B1 (en) 2001-05-03 2015-01-28 Hoffmann La Roche Pharmaceutical dosage form of amorphous nelfinavir mesylate
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
IL154318A (en) * 2003-02-06 2010-05-31 Sarah Herzog Memorial Hospital Pharmaceutical compositions for the treatment of movement disorders
US20060094744A1 (en) 2004-09-29 2006-05-04 Maryanoff Cynthia A Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
CA2602626A1 (en) 2005-04-11 2006-10-19 Yale University Method of treating schizophrenia prodrome
CN101309917B (zh) 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
WO2008030382A1 (en) 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
IL188681A0 (en) 2008-01-09 2008-12-29 Amino Acid Solutions Inc Pharmaceutical compositions and methods utilizing a d-amino acid
WO2012019106A2 (en) 2010-08-06 2012-02-09 Board Of Regents Of The University Of Nebraska Positive and negative modulators of nmda receptors
US9040581B1 (en) 2013-02-21 2015-05-26 The Florida State University Research Foundation, Inc. Methods of treatment using D-serine
WO2014191992A1 (en) * 2013-05-28 2014-12-04 Sarah Herzog Memorial Hospital-Ezrath Nashim Autoimmune-induced glutamatergic receptor dysfunction methods and treatments
WO2014205074A2 (en) 2013-06-18 2014-12-24 The Trustees Of Columbia University In The City Of New York Devices, compositions and methods for imaging with raman scattering
WO2015160470A2 (en) * 2014-03-20 2015-10-22 The Trustees Of Princeton University Nadph production by the 10-formyl-thf pathway, and its use in the diagnosis and treatment of disease
GB201521903D0 (en) 2015-12-11 2016-01-27 Electrophoretics Ltd Isorbaric mass labels
EP3465202B1 (en) 2016-06-02 2023-07-05 Metabolon, Inc. Mass spectrometry method for detection and quantitation of metabolites
CN111491629A (zh) * 2017-11-22 2020-08-04 康塞特医药品公司 D-丝氨酸的氘化类似物及其用途
WO2020243650A1 (en) 2019-05-29 2020-12-03 Concert Pharmaceuticals, Inc. Deuterated analogs of d-serine and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582931A (en) * 1984-12-24 1986-04-15 Merck & Co., Inc. Preparation of 2-Deutero-D-serine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
網路文獻 TOMOKAZU ITO ET AL, "Role of zinc ion for catalytic activity in d-serine dehydratase from Saccharomyces?cerevisiae : Role of zinc in Eukaryotic d-serine dehydratase", FEBS JOURNAL, GB, (20120201), vol. 279, no. 4, , pages 612-624 *

Also Published As

Publication number Publication date
AU2025200345A1 (en) 2025-02-13
US10668036B2 (en) 2020-06-02
JP2023123476A (ja) 2023-09-05
CA3082834A1 (en) 2019-05-31
US20200390732A1 (en) 2020-12-17
US20200368193A1 (en) 2020-11-26
JP7733058B2 (ja) 2025-09-02
KR20200103662A (ko) 2020-09-02
US20190328692A1 (en) 2019-10-31
IL274585B1 (en) 2025-09-01
KR102916897B1 (ko) 2026-01-26
JP2021504326A (ja) 2021-02-15
MX2020005336A (es) 2020-08-13
US12029712B2 (en) 2024-07-09
JP7518765B2 (ja) 2024-07-18
IL274585B2 (en) 2026-01-01
US20250000830A1 (en) 2025-01-02
EP4560024A2 (en) 2025-05-28
TW201924668A (zh) 2019-07-01
WO2019104179A1 (en) 2019-05-31
IL274585A (en) 2020-06-30
CN111491629A (zh) 2020-08-04
BR112020010156A2 (pt) 2020-11-10
PL3713557T3 (pl) 2025-09-22
EP3713557B1 (en) 2025-03-12
IL322463A (en) 2025-09-01
EP4560024A3 (en) 2025-08-20
EP3713557A1 (en) 2020-09-30
AU2018371784A1 (en) 2020-05-28
AU2018371784B2 (en) 2024-10-17
WO2019104179A4 (en) 2019-08-01
JP2025138735A (ja) 2025-09-25

Similar Documents

Publication Publication Date Title
TWI886093B (zh) D-絲胺酸之氘化類似物及其用途
TW202416974A (zh) 標靶細胞外HSP90(eHSP90)之放射性藥物及其用途
US20120071554A1 (en) Deuterated 2-propylpentanoic acid compounds
US20220313640A1 (en) Deuterated analogs of d-serine and uses thereof
KR20260022936A (ko) 비장을 표적으로 하는 지질 나노입자
EA050051B1 (ru) Дейтерированные аналоги d-серина и их применение
US10843993B2 (en) Deuterated idebenone
US20220218641A1 (en) Methods of treatment with deuterated analogs of d-serine
TWI913215B (zh) 減少尿液sCD163之C5aR抑制劑
CN121930131A (zh) 化合物及其在治疗nmdar相关疾病中的用途
EP4304655A1 (en) Fatty acid-bifunctional degrader conjugates and their methods of use
JP2025538979A (ja) 結晶性カルバゾール誘導体およびその製造方法
WO2020046941A1 (en) Crystalline forms of substituted dihydroindene-4-carboxamide compounds and methods of preparing and using same